Skip to content

Inspection Record

Divi's Laboratories — FDA 483 Findings

US FDAInspected 2016-12-06Published 2016-12-28 5 findingsEquipment and facilityDeviation, CAPA, and investigationOther quality systemComputer system validation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Facilities and equipment are not maintained to ensure the purity, quality, strength and identity of the API Specifically, we observed the following deficiencies: .

2Deviation, CAPA, and investigation

Failure to conduct a thorough investigation.

3Other quality system

Your R&D division guides quality and production to commence activities inconsistent with CGMPs.

4Computer system validation

Proper controls are not exercised over computerized systems used for analytical testing to ensure drug products meet their specified quality attributes.

5Other quality system

Documentation and records are either not maintained or inaccurate/falsified 1.

A record as of the US FDA document published on 2016-12-28. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Divi's Laboratories company profile — full historyAll US FDA findings US FDA documents, 2016 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.